Cremophor ELHans Gelderblom, Alex Sparreboom, Jaap Verweij et al.|European Journal of Cancer|2001Cited by 1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, Jaap Verweij et al.|The Lancet Oncology|2014Cited by 1.2k
Soft tissue sarcomas of adults: state of the translational science.Ernest C. Borden, Murray F. Brennan, Laurence H. Baker et al.|PubMed|2003Cited by 616
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group TrialAxel Le Cesne, Ole S. Nielsen, Sjoerd Rodenhuis et al.|Journal of Clinical Oncology|2005Cited by 421
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular targetJaap Verweij, Ole S. Nielsen, A. van Oosterom et al.|European Journal of Cancer|2003Cited by 403